Physician profile
Manish Parikh
NPI 1457390791
$5,028.36
in general payments reported to CMS, 2019-2025
23 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $123 · 2021: $234 · 2022: $339 · 2023: $284 · 2024: $2,412 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152 · Travel and Lodging: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.94 |
| Travel and Lodging | $713.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,459.83 | 2024 | Neurostar Tms Therapy System |
| Abbvie INC. | $1,215.57 | 2021-2025 | |
| Indivior INC. | $596.92 | 2019-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $296.72 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.79 | 2025 | Caplyta |
| Braeburn INC. | $226.84 | 2024-2025 | Brixadi |
| Allergan, INC. | $207.09 | 2019-2020 | |
| Boston Scientific Corporation | $141.47 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $102.40 | 2024 | Rexulti |
| Orexo US, INC. | $90.84 | 2019-2023 | Zubsolv |
| Gilead Sciences, INC. | $89.60 | 2024 | Epclusa |
| Pear Therapeutics (US), INC. | $57.97 | 2021-2022 | |
| Novo Nordisk INC | $41.97 | 2019-2020 | |
| Tris Pharma INC | $41.27 | 2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $23.13 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $22.08 | 2024 | Hetlioz, Fanapt |
| Vertex Pharmaceuticals Incorporated | $21.33 | 2025 | |
| Collegium Pharmaceutical, INC. | $20.32 | 2025 | Jornay Pm |
| Lundbeck LLC | $19.98 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $17.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.50 | 2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $15.79 | 2024 | Cobenfy |
| Alkermes, INC. | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.